Literature DB >> 15583288

Genetic profile of an Oka varicella vaccine virus variant isolated from an infant with zoster.

Andreas Sauerbrei1, Elena Rubtcova, Peter Wutzler, D Scott Schmid, Vladimir N Loparev.   

Abstract

Varicella virus vaccine strain Oka (V-Oka) has in rare cases caused zoster in vaccinated people. Despite broad usage of V-Oka, little is known about varicella-zoster virus genomic sequence variation of strains in vaccine and isolates from patients with vaccine adverse events. Direct sequencing of 20 regions of V-Oka-GSK was compared to the sequences of the original V-Oka-Biken, GlaxoSmithKline Oka vaccine (V-Oka-GSK), and Oka-parental (P-Oka) strains. We analyzed single nucleotide polymorphisms (SNP) differentiating the Oka parental and Oka vaccine strains identified in open reading frames (ORFs) 6, 9A, 10, 21, 31, 39, 50, 51, 52, 54, 55, and 59 and eight base substitutions within ORF 62. Sixteen of these SNP impose an amino acid change in the corresponding gene product. The genotypic analysis revealed that (i) both V-Oka-GSK and V-Oka-Biken comprise mixtures of strains represented in variable proportion from lot to lot; (ii) V-Oka-GSK/zoster isolated from the zoster patient had six wild-type SNP in ORF 9A, 10, 21, 52, 55, and 62 (mutation 108838); (iii) none of the six revertant SNP would reliably discriminate Oka vaccine from the wild type; and (iv) the genomic variation found in V-Oka/zoster might be associated with changes in the biological behavior of the virus. Further studies will be needed to identify potential virulence factors in variant vaccine strains.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15583288      PMCID: PMC535228          DOI: 10.1128/JCM.42.12.5604-5608.2004

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  26 in total

1.  Herpes zoster after varicella immunization.

Authors:  M G Liang; K A Heidelberg; R M Jacobson; M T McEvoy
Journal:  J Am Acad Dermatol       Date:  1998-05       Impact factor: 11.527

2.  Production and quality control of the Oka-strain live varicella vaccine.

Authors:  E D'Hondt; E Berge; G Colinet; M Duchene; J Peetermans
Journal:  Postgrad Med J       Date:  1985       Impact factor: 2.401

3.  Live vaccine used to prevent the spread of varicella in children in hospital.

Authors:  M Takahashi; T Otsuka; Y Okuno; Y Asano; T Yazaki
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

4.  Varicella-zoster virus (VZV) transcription during latency in human ganglia: detection of transcripts mapping to genes 21, 29, 62, and 63 in a cDNA library enriched for VZV RNA.

Authors:  R J Cohrs; M Barbour; D H Gilden
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

5.  Varicella-zoster virus (VZV) open reading frame 10 protein, the homolog of the essential herpes simplex virus protein VP16, is dispensable for VZV replication in vitro.

Authors:  J I Cohen; K Seidel
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

6.  Global identification of three major genotypes of varicella-zoster virus: longitudinal clustering and strategies for genotyping.

Authors:  Vladimir N Loparev; Antonio Gonzalez; Marlene Deleon-Carnes; Graham Tipples; Helmut Fickenscher; Einar G Torfason; D Scott Schmid
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

7.  Varicella-zoster virus (VZV) virion-associated transactivator open reading frame 62 protein enhances the infectivity of VZV DNA.

Authors:  M Moriuchi; H Moriuchi; S E Straus; J I Cohen
Journal:  Virology       Date:  1994-04       Impact factor: 3.616

8.  Varicella-zoster virus gene 51 complements a herpes simplex virus type 1 UL9 null mutant.

Authors:  D Chen; E C Stabell; P D Olivo
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

9.  Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates.

Authors:  P LaRussa; O Lungu; I Hardy; A Gershon; S P Steinberg; S Silverstein
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

10.  The epidemiology of varicella and its complications.

Authors:  P W Choo; J G Donahue; J E Manson; R Platt
Journal:  J Infect Dis       Date:  1995-09       Impact factor: 5.226

View more
  9 in total

1.  Complete-genome phylogenetic approach to varicella-zoster virus evolution: genetic divergence and evidence for recombination.

Authors:  Peter Norberg; Jan-Ake Liljeqvist; Tomas Bergström; Scott Sammons; D Scott Schmid; Vladimir N Loparev
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

2.  Stable and consistent genetic profile of Oka varicella vaccine virus is not linked with appearance of infrequent breakthrough cases postvaccination.

Authors:  Ventzislav Vassilev
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

3.  Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-associated herpes zoster.

Authors:  Mark L Quinlivan; Nancy J Jensen; Kay W Radford; D Scott Schmid
Journal:  J Clin Microbiol       Date:  2012-02-29       Impact factor: 5.948

4.  Molecular analysis of varicella vaccines and varicella-zoster virus from vaccine-related skin lesions.

Authors:  Sonja Thiele; Aljona Borschewski; Judit Küchler; Marc Bieberbach; Sebastian Voigt; Bernhard Ehlers
Journal:  Clin Vaccine Immunol       Date:  2011-05-11

5.  Complete DNA sequences of two oka strain varicella-zoster virus genomes.

Authors:  Sueli L Tillieux; Wendy S Halsey; Elizabeth S Thomas; John J Voycik; Ganesh M Sathe; Ventzislav Vassilev
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

6.  Identification of five major and two minor genotypes of varicella-zoster virus strains: a practical two-amplicon approach used to genotype clinical isolates in Australia and New Zealand.

Authors:  Vladimir N Loparev; Elena N Rubtcova; Vanda Bostik; Dhwani Govil; Christopher J Birch; Julian D Druce; D Scott Schmid; Margaret C Croxson
Journal:  J Virol       Date:  2007-09-26       Impact factor: 5.103

7.  [Herpes zoster after varicella-zoster vaccination].

Authors:  M Fahlbusch; U Wesselmann; P Lehmann
Journal:  Hautarzt       Date:  2013-02       Impact factor: 0.751

8.  Transmission of varicella vaccine virus, Japan.

Authors:  Taketo Otsuka; Yasuyuki Gomi; Naoki Inoue; Makoto Uchiyama
Journal:  Emerg Infect Dis       Date:  2009-10       Impact factor: 6.883

9.  Deep Sequencing of Distinct Preparations of the Live Attenuated Varicella-Zoster Virus Vaccine Reveals a Conserved Core of Attenuating Single-Nucleotide Polymorphisms.

Authors:  Daniel P Depledge; Koichi Yamanishi; Yasuyuki Gomi; Anne A Gershon; Judith Breuer
Journal:  J Virol       Date:  2016-09-12       Impact factor: 6.549

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.